468 Individually dose-adjusted treatment with epirubicin and paclitaxel with or without capecitabine as 1st line treatment in metastatic breast cancer. A randomized multicenter trial

T.Hatschek; Z.Einbeigi; T.Walz; M.Malmberg; N.Loman; L.Carlsson; M.S?derberg; B.Linderholm; B.Lindh; M.Sundqvist

首页> 外文期刊>European Journal of Cancer Supplements >468 Individually dose-adjusted treatment with epirubicin and paclitaxel with or without capecitabine as 1st line treatment in metastatic breast cancer. A randomized multicenter trial

【24h】

468 Individually dose-adjusted treatment with epirubicin and paclitaxel with or without capecitabine as 1st line treatment in metastatic breast cancer. A randomized multicenter trial

机译：468在转移性乳腺癌中，以表柔比星和紫杉醇联合或不联合卡培他滨作为个体剂量调整治疗的一线治疗。一项随机的多中心试验

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2010年第3期|共2页
作者
T.Hatschek; Z.Einbeigi; T.Walz; M.Malmberg; N.Loman; L.Carlsson; M.S?derberg; B.Linderholm; B.Lindh; M.Sundqvist;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: A randomized multicenter trial [J] . HatschekT., CarlssonL., EinbeigiZ., Breast cancer research and treatment. . 2012,第3期

机译：单独或联合使用表柔比星和紫杉醇联合或不联合卡培他滨作为转移性乳腺癌一线化疗的治疗：一项随机的多中心试验
2. Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial [J] . T. Hatschek, L. Carlsson, Z. Einbeigi, Breast Cancer Research and Treatment . 2012,第3期

机译：单独或联合使用表柔比星和紫杉醇联合或不联合卡培他滨作为转移性乳腺癌一线化疗的治疗：一项随机的多中心试验
3. Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: Efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group [J] . LückH.-J., DuBoisA., LoiblS., Breast cancer research and treatment. . 2013,第3期

机译：卡培他滨联合紫杉醇与表柔比星联合紫杉醇作为转移性乳腺癌的一线治疗：AGO乳腺癌研究小组进行的一项随机III期试验的疗效和安全性结果
4. IG-001—A non-biologic micellar paclitaxel formulation for the treatment of metastatic Breast cancer [C] . Motamed Kouros, Hwang Larn, Hsiao Chao, IEEE International Conference on Nano/Molecular Medicine and Engineering . 2013

机译：IG-001—用于治疗转移性乳腺癌的非生物胶束紫杉醇制剂
5. Cost-Benefit Analysis of Nanoparticle Albumin-Bound Paclitaxel versus Solvent-Based Paclitaxel for the Treatment of Metastatic Breast Cancer in the United States [D] . Vichansavakul, Kittaya 2013

机译：纳米白蛋白结合紫杉醇与溶剂型紫杉醇在美国治疗转移性乳腺癌的成本效益分析
6. A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study [O] . Patrizia Vici, Giuseppe Colucci, Francesco Giotta, 2011

机译：表柔比星/长春瑞滨与聚乙二醇化脂质体阿霉素/长春瑞滨作为晚期乳腺癌的一线治疗的多中心前瞻性II期随机试验。 GOIM研究
7. Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer : a randomized multicenter trial [O] . Hatschek, T, Carlsson, L, Einbeigi, Z, 2012

机译：单独或联合使用表柔比星和紫杉醇联合或不联合卡培他滨作为转移性乳腺癌一线化疗的治疗：一项随机的多中心试验

468 Individually dose-adjusted treatment with epirubicin and paclitaxel with or without capecitabine as 1st line treatment in metastatic breast cancer. A randomized multicenter trial

著录项

相似文献

相关主题

期刊订阅